Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

144
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
144
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

184
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
184
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.6K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.6K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

111
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
111
Drug Regulation01:25

Drug Regulation

2.6K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.6K
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

602
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
602

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Access to GLP-1 Receptor Agonists for Weight Management in Medicare: The GLP-1 Bridge Demonstration.

Annals of internal medicine·2026
Same author

Evidence and Pricing: Bridging the Comparative Effectiveness Gap in Federal and State Drug Policy.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

Patient out-of-pocket costs and rheumatology biosimilar competition.

Journal of managed care & specialty pharmacy·2026
Same author

Assessment of IPAY 2027 Medicare drug price negotiation maximum fair prices with prices in most-favored nation reference countries.

Journal of managed care & specialty pharmacy·2026
Same author

Spending Impact of the First 10 Drugs Selected for Medicare Drug Price Negotiation in the United States.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026
Same author

Reestimation of Medicare Spending for Semaglutide After Most Favored Nation and Medicare Drug Price Negotiation Announcements.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2026

Related Experiment Video

Updated: Dec 20, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

Pharmacoeconomic Evaluations: Guidelines for Drug Purchasers.

Paul C Langley1, Sean D Sullivan2

  • 1Associate Professor, Center for Pharmaceutical Economics, College of Pharmacy, University of Arizona, Tucson.

Journal of Managed Care & Specialty Pharmacy
|May 29, 2020
PubMed
Summary

New guidelines offer a systematic approach for healthcare organizations to evaluate pharmaceutical products, considering clinical outcomes and overall system costs for better drug purchasing decisions.

Keywords:
CostsFormulariesGuidelinesManaged care organizationsNew drugsOutcomesPharmaceutical industryPharmacoeconomics

More Related Videos

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

2.2K
Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
06:40

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

1.7K

Related Experiment Videos

Last Updated: Dec 20, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation
08:47

Experimental Quantification of Interactions Between Drug Delivery Systems and Cells In Vitro: A Guide for Preclinical Nanomedicine Evaluation

Published on: September 28, 2022

2.2K
Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
06:40

Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets

Published on: February 23, 2024

1.7K

Area of Science:

  • Health Economics
  • Pharmaceutical Policy
  • Clinical Decision Making

Background:

  • Healthcare organizations require robust methods for evaluating pharmaceutical products.
  • Informed drug purchasing decisions necessitate comparative clinical and economic analysis.
  • Existing evaluation methods may not fully capture the system-wide impact of new therapies.

Purpose of the Study:

  • To propose guidelines for US healthcare organizations to make sound drug purchasing decisions.
  • To provide a structured framework for evaluating pharmaceutical products based on a therapy intervention approach.
  • To enhance consistency in how managed care purchasers evaluate drugs for formulary inclusion.

Main Methods:

  • Developed guidelines based on a therapy intervention approach.
  • Incorporated a structured framework for evaluating drug products.
  • Focused on assessing the impact of new drugs on overall health system costs.
  • Intended for use by managed care organizations (MCOs) in the US.

Main Results:

  • The guidelines offer a systematic approach for identifying the cost and clinical outcomes impact of drug therapies.
  • The framework accounts for patient population characteristics and patient redistribution among treatment categories.
  • Provides an analysis model that extends beyond traditional partial cost-outcomes approaches.
  • Specifies key information elements for pharmacoeconomic analysis, including system impact assessments.

Conclusions:

  • The proposed guidelines provide a comprehensive model for pharmacoeconomic analysis.
  • These guidelines enable a more accurate assessment of a new drug's impact on overall healthcare costs and outcomes.
  • Facilitates more informed and systematic drug purchasing decisions by managed care organizations.